wakeboarding, kite surfing). The product is also ideal for patients
recovering from ACL and other knee ligament surgeries, as it
features DJO’s proprietary four-points-of-leverage technology,
an innovation that puts a posterior load on the tibia and helps
reduce ACL strain by 50 percent.
“I was so blessed to be wearing my @donjoyperformance
braces, which you can see if you look close [at this frame grab
from the 2011 world record wave],” McNamara wrote on his
Facebook page last spring as he recovered from a gnarly winter
wipeout in Mavericks (a break off northern California) that frac-
tured his left humerus bone in four places. “Right then the white
water landed on me like a ton of bricks. Without the [braces] it
most likely would have buckled my knee. So grateful for the sup-
port no pun intended.”
That feeling likely is mutual, as DJO depends partly on pro-
fessional endorsements to maintain its edge in the global brac-
ing sector and grow sales in the company’s largest moneymaking
segment, Bracing and Vascular. Despite a long list of well-known
users, McNamara was really the only big-name athlete to faith-
fully promote DonJoy braces last year, albeit the company did
maintain a steady crop of Facebook testimonials from bullfighters
and rookie participants of college softball, lacrosse, and football.
While it is virtually impossible to gauge the fiscal benefit of
professional sports endorsements on DJO’s overall sales, it is
equally impractical to dismiss as coincidental the Bracing and
Vascular division’s flat revenue last year. The segment posted a
0.7 percent ($3.69 million) loss from 2015, slipping to $522.6 million in fiscal 2016 (year ended Dec. 31).
DJO’s official explanation for the loss was market pressure
and fewer Dr. Comfort footwear sales due to an enterprise resource planning software switch. Not surprisingly, the company
ignored last year’s drought in product testimonials, choosing instead to note the Bracing and Vascular segment’s loss was offset
by growth in its OfficeCare channel and direct consumer devices.
Bracing and Vascular’s 2016 deficit was also offset in part by a
miniscule 0.4 percent increase in Recovery Sciences revenue. Proceeds rose $800,000 to $157 million on strong sales of Complex
muscle stimulator devices, though further growth was inhibited
by a decline in CMF bone growth stimulators.
Surgical Implant revenue hikes more than compensated for
its two struggling brethren—sales blossomed 29. 4 percent last
year to $174.5 million due to strong demand for new hip, knee,
and shoulder products. The segment also benefited from the 2015
purchase of Biomet Cobalt Bone Cement, Optivac Cement Mixing Accessories, and the Discovery Elbow System from Zimmer
Biomet (the latter device marked the company’s first foray into
the global elbow sector). DJO earned $6.3 million from former
Zimmer Biomet products in 2016.
International segment sales neutralized sagging Bracing/Vas-cular revenue as well. Proceeds rose 1.7 percent to $301.2 million,
though the increase swelled to 3. 4 percent in constant currency
when $5.2 million in foreign exchange rates is excluded from the
total. DJO attributed the growth in this division to strong direct
LOW-8622 Half Page Ad 2017_3.375X9.5.indd 1 2/13/17 11: 51 AM